1. Home
  2. SKYE vs PMM Comparison

SKYE vs PMM Comparison

Compare SKYE & PMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • PMM
  • Stock Information
  • Founded
  • SKYE 2012
  • PMM 1989
  • Country
  • SKYE United States
  • PMM United States
  • Employees
  • SKYE N/A
  • PMM N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • PMM Investment Managers
  • Sector
  • SKYE Health Care
  • PMM Finance
  • Exchange
  • SKYE Nasdaq
  • PMM Nasdaq
  • Market Cap
  • SKYE 176.8M
  • PMM 283.6M
  • IPO Year
  • SKYE N/A
  • PMM N/A
  • Fundamental
  • Price
  • SKYE $5.96
  • PMM $6.18
  • Analyst Decision
  • SKYE Strong Buy
  • PMM
  • Analyst Count
  • SKYE 4
  • PMM 0
  • Target Price
  • SKYE $19.25
  • PMM N/A
  • AVG Volume (30 Days)
  • SKYE 324.0K
  • PMM 118.3K
  • Earning Date
  • SKYE 01-01-0001
  • PMM 01-01-0001
  • Dividend Yield
  • SKYE N/A
  • PMM 4.68%
  • EPS Growth
  • SKYE N/A
  • PMM N/A
  • EPS
  • SKYE N/A
  • PMM 0.23
  • Revenue
  • SKYE N/A
  • PMM N/A
  • Revenue This Year
  • SKYE N/A
  • PMM N/A
  • Revenue Next Year
  • SKYE N/A
  • PMM N/A
  • P/E Ratio
  • SKYE N/A
  • PMM $26.52
  • Revenue Growth
  • SKYE N/A
  • PMM N/A
  • 52 Week Low
  • SKYE $1.44
  • PMM $5.00
  • 52 Week High
  • SKYE $19.41
  • PMM $6.42
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 35.77
  • PMM 50.96
  • Support Level
  • SKYE $5.77
  • PMM $6.14
  • Resistance Level
  • SKYE $6.16
  • PMM $6.22
  • Average True Range (ATR)
  • SKYE 0.71
  • PMM 0.05
  • MACD
  • SKYE 0.13
  • PMM -0.01
  • Stochastic Oscillator
  • SKYE 33.81
  • PMM 35.00

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About PMM Putnam Managed Municipal Income Trust

Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.

Share on Social Networks: